Abstract
Background. We have shown that rIL-2 administration in recurrent head and neck cancers induces a tumor-specific T-lymphocyte reactivity and tumor regression; in a pilot study we have shown a safe and effective administration of rIL2 after cisplatin + 5-fluorouracil. Long-term results are not known. Methods. Thirty patients with recurrent/persistent head and neck cancer were treated with cisplatin (100 mg/m2) d.1.5-fluorouracil (1 gr/m2/d c.i. 96 h), and SQ rIL-2 (4.5 M IU day 8 to 12 and 15 to 19) every 3 weeks. Results. The overall response rate was 53.3% (95% Cl; 34.4-72.3%): 26.6% complete response (CR) (8 patients) and 26.6% partial response (PR) (8 patients); 6 patients had SD (20%), 8 had PD (26.6%). The median follow-up was 36 months (range, 28-44). The median CR duration is 16.2 months (8.5-39+); the median survival duration of this group has not been reached. The median PR duration was 7.2 months (3-10); the median survival was 13.3 months (10-26). The median overall survival was 14 months. Conclusions. The most impressive finding is the very long survival of CRs patients. This outcome has been reported in other cancer patients with a CR after IL-2 therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 298-304 |
| Number of pages | 7 |
| Journal | Head and Neck |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2001 |
Fingerprint
Keywords
- Chemotherapy
- Cisplatin
- Head and neck cancer
- IL-2
- Immunotherapy
ASJC Scopus subject areas
- Otorhinolaryngology
Cite this
Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. / Airoldi, Mario; De Stefani, Antonella; Marchionatti, Sara; Pedani, Fulvia; Gabriele, Pietro; Ragona, Riccardo; Cortesina, Giorgio; Bumma, Cesare.
In: Head and Neck, Vol. 23, No. 4, 2001, p. 298-304.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy
AU - Airoldi, Mario
AU - De Stefani, Antonella
AU - Marchionatti, Sara
AU - Pedani, Fulvia
AU - Gabriele, Pietro
AU - Ragona, Riccardo
AU - Cortesina, Giorgio
AU - Bumma, Cesare
PY - 2001
Y1 - 2001
N2 - Background. We have shown that rIL-2 administration in recurrent head and neck cancers induces a tumor-specific T-lymphocyte reactivity and tumor regression; in a pilot study we have shown a safe and effective administration of rIL2 after cisplatin + 5-fluorouracil. Long-term results are not known. Methods. Thirty patients with recurrent/persistent head and neck cancer were treated with cisplatin (100 mg/m2) d.1.5-fluorouracil (1 gr/m2/d c.i. 96 h), and SQ rIL-2 (4.5 M IU day 8 to 12 and 15 to 19) every 3 weeks. Results. The overall response rate was 53.3% (95% Cl; 34.4-72.3%): 26.6% complete response (CR) (8 patients) and 26.6% partial response (PR) (8 patients); 6 patients had SD (20%), 8 had PD (26.6%). The median follow-up was 36 months (range, 28-44). The median CR duration is 16.2 months (8.5-39+); the median survival duration of this group has not been reached. The median PR duration was 7.2 months (3-10); the median survival was 13.3 months (10-26). The median overall survival was 14 months. Conclusions. The most impressive finding is the very long survival of CRs patients. This outcome has been reported in other cancer patients with a CR after IL-2 therapy.
AB - Background. We have shown that rIL-2 administration in recurrent head and neck cancers induces a tumor-specific T-lymphocyte reactivity and tumor regression; in a pilot study we have shown a safe and effective administration of rIL2 after cisplatin + 5-fluorouracil. Long-term results are not known. Methods. Thirty patients with recurrent/persistent head and neck cancer were treated with cisplatin (100 mg/m2) d.1.5-fluorouracil (1 gr/m2/d c.i. 96 h), and SQ rIL-2 (4.5 M IU day 8 to 12 and 15 to 19) every 3 weeks. Results. The overall response rate was 53.3% (95% Cl; 34.4-72.3%): 26.6% complete response (CR) (8 patients) and 26.6% partial response (PR) (8 patients); 6 patients had SD (20%), 8 had PD (26.6%). The median follow-up was 36 months (range, 28-44). The median CR duration is 16.2 months (8.5-39+); the median survival duration of this group has not been reached. The median PR duration was 7.2 months (3-10); the median survival was 13.3 months (10-26). The median overall survival was 14 months. Conclusions. The most impressive finding is the very long survival of CRs patients. This outcome has been reported in other cancer patients with a CR after IL-2 therapy.
KW - Chemotherapy
KW - Cisplatin
KW - Head and neck cancer
KW - IL-2
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=0035088068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035088068&partnerID=8YFLogxK
U2 - 10.1002/hed.1034
DO - 10.1002/hed.1034
M3 - Article
VL - 23
SP - 298
EP - 304
JO - Head and Neck Surgery
JF - Head and Neck Surgery
SN - 1043-3074
IS - 4
ER -